CDK13 and prostate carcinoma: The necessity of targeting both CDK12 and CDK13 to achieve optimal enhancement of ICB response was further validated with an additional prostate cancer syngeneic model harboring Cdk12 loss and Trp53 depletion (Cdk12KO-sgp53), which was previously established (13).